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The risk of death in hemodialysis patients treated with
calcium-containing phosphate binders or sevelamer is not
known. We assessed all-cause mortality in 127 patients new
to hemodialysis assigned to calcium-containing binders or
sevelamer after a median follow-up of 44 months from
randomization. This was a predetermined secondary end
point of a randomized clinical trial designed to assess
progression of coronary artery calcium (CAC) scores in the
two treatment arms. Thirty-four deaths occurred during the
follow-up period: 23 in subjects randomized to calcium-
containing phosphate binders and 11 in subjects randomized
to sevelamer. Baseline CAC score was a significant predictor
of mortality after adjustment for age, race, gender, and
diabetes with increased mortality proportional to baseline
score (P¼ 0.002). Mortality was borderline significantly lower
in subjects randomized to sevelamer (5.3/100 patient years,
confidence interval (CI) (2.2–8.5) compared to those
randomized to calcium-containing binders (10.6/100 patient
years, CI 6.3–14.9) (P¼ 0.05). The greater risk of death for
patients treated with calcium-containing phosphate binders
persisted after full multivariable adjustment (P¼ 0.016,
hazard ratio 3.1, CI 1.23–7.61). In subjects new to
hemodialysis baseline CAC score was a significant predictor
of all-cause mortality. Treatment with sevelamer was
associated with a significant survival benefit as compared to
the use of calcium-containing phosphate binders.
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It has been well documented that patients undergoing
hemodialysis demonstrate extensive coronary artery calcifi-
cation (CAC) compared to patients with normal kidney
function.1–5 Observational and experimental data suggest that
the risk of CAC is related to abnormalities in mineral
metabolism and that there is a direct relationship between
serum phosphorus, serum calcium, and serum calcium
phosphorus product (Ca P) with increased mortality.6–11 In
recent trials, investigators have reported that CAC progres-
sion can be attenuated in hemodialysis subjects treated with
sevelamer as opposed to those treated with calcium-contain-
ing phosphate binders.1–3 However, it is still unknown
whether phosphate binder choice affects clinical outcomes.
Accordingly, for the purpose of this study, we examined the
relationship between phosphate binder choice (calcium-
containing phosphate binders versus sevelamer), CAC
assessed by electron beam computed tomography (EBCT),
and mortality, in a cohort of incident hemodialysis subjects.
Assessment of all-cause mortality was a secondary end point
of a randomized trial previously reported whose primary end
point was change in CAC at 18 months.2
RESULTS
The baseline clinical and laboratory characteristics of the 127
subjects included in this analysis are shown in Table 1. There
were no significant baseline differences between the sevelamer
and calcium-containing binder groups.
At the end of follow-up, 34 total deaths were recorded: 11
in the sevelamer group and 23 in the calcium binder group.
Baseline CAC score was a significant predictor of mortality as
shown in Figure 1. Subjects with no evidence of CAC had a
significantly lower mortality rate (3.3/100 patient years,
confidence interval (CI) 0.4–6.1) as compared to subjects
with a CAC score 1–400 (mortality rate 7.0/100 patient years,
CI 2.7–11.4) and those with a CAC score 4400 (mortality
rate 14.7/100 patient years, CI 8.1–21.4) (P¼ 0.002). After
adjustment of baseline CAC score for age, race, gender, and
diabetes, the presence of a baseline CAC score 4400
remained significantly associated with increased mortality
(hazard ratio¼ 4.5, P¼ 0.016, CI 1.33–15.14).
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CAC scores were similarly distributed at baseline in
both treatment groups (CAC¼ 0: calcium 33%, sevelamer
40%; CAC 1–400: calcium 36%, sevelamer 30%; CAC 4400:
calcium 31%, sevelamer 30%). Mortality was borderline
significantly higher in subjects treated with calcium
binders (10.6/100 patient years, CI 6.3–14.9) compared
to those randomized to sevelamer (5.3/100 patient years,
CI 2.2–8.5, P¼ 0.05). Factors associated with increased
mortality in univariate analysis included phosphate binder
assignment (P¼ 0.06), baseline CAC score (P¼ 0.003),
baseline history of atherosclerotic cardiovascular disease
(P¼ 0.02), and baseline C-reactive protein (P¼ 0.06). After
multivariable adjustment for age, race, gender, diabetes,
albumin, Kt/V, history of atherosclerotic cardiovascular
disease, C-reactive protein, and baseline CAC score, a
significant increase in mortality was observed for calcium-
treated subjects (P¼ 0.02, hazard ratio 3.1, CI 1.23–7.61)
(Figure 2).
DISCUSSION
This analysis represents the secondary end point of a
randomized clinical trial and is notable for describing that
baseline CAC score and choice of phosphate binder (calcium
versus sevelamer) are independent predictors of mortality in
subjects who are new to hemodialysis.
It is well recognized that vascular calcification is common
and progressive in patients with advanced chronic kidney
disease. Several lines of evidence suggest that cardiovascular
calcification is a marker of poor prognosis in chronic kidney
disease stage 5, but only one study, so far, has addressed the
risk of mortality in patients that underwent quantitative
EBCT imaging for CAC.12 The current trial confirms the
finding that the severity of CAC at the time of initiation of
hemodialysis is an important predictor of long-term survival.
Even after adjustment for age, race, gender, and diabetes, a
baseline CAC 4400 was associated with a greater than
fourfold increase in mortality.
Table 1 | Baseline characteristics of study subjects
Sevelamer
(n=60)
Calcium salts
(n=67) P-value
Age (mean7s.d.) 56714.8 58714.8 NS
Male (%) 58 64 NS
Race (%)
Caucasian 43 39 NS
Black 27 37
Hypertension (%) 95 98 NS
Diabetes mellitus (%) 60 56 NS
Congestive Heart Failure (%) 13 18 NS
ASCVDa (%) 37 22 0.08
Dyslipidemia (%) 30 33 NS
Smoking (active or former, %) 66 58 NS
‘Statin’ medication use (%) 36 30 NS
Ace Inhibitor medication use (%) 50 55 NS
Cholesterol total (mg/dl) 159743 158734 NS
Cholesterol LDL (mg/dl) 73734 75729 NS
Hemoglobin (g/l) 11.671.8 12.072.1 NS
C-reactive protein (mg/l) 6.776.4 8.2711.3 NS
Albumin (g/dl) 3.570.6 3.670.5 NS
Calcium (corrected)b (mg/dl) 9.370.9 9.370.8 NS
Phosphorus (mg/dl) 5.271.6 5.371.4 NS
Ca P (corrected) (mg2/dl2) 48714 49713 NS
Intact PTH 3557317 3587360 NS
Baseline CACS (mean) 61671436 58671190 NS
ASCVD, atherosclerotic cardiovascular disease; CACS, coronary artery calcium score;
Ca P, calciumphosphorus product; LDL, low-density lipoprotein; NS, nonsigni-
ficant; PTH, parathyroid hormone.
aASCVD: atherosclerotic cardiovascular disease (history of previous myocardial
infarction, angina pectoris, angioplasty with/without stent, coronary artery bypass
graft, angiographic evidence of atherosclerotic disease, cerebrovascular disease,
claudication, lower extremity interventions for atherosclerosis, aortic aneurysm).
bCorrected calcium: serum calcium adjusted for serum albumin: total measured
calcium + 0.8 (4.0 albumin g/dl).
P=0.002
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Figure 1 | Adjusted survival by baseline CAC score. Multivariable
adjusted (age, race, gender, diabetes) association between baseline
CAC score and survival. P-value represents significance across all
three groups.
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Figure 2 | Adjusted survival by phosphate binder assignment.
Multivariable adjusted (age, race, gender, diabetes, history of
atherosclerotic cardiovascular disease, C-reactive protein, albumin,
Kt/V, and baseline CAC score) association between phosphate binder
treatment assignment (calcium versus sevelamer) and survival.
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Three previous randomized clinical trials have shown that
the use of a calcium-containing phosphate binder is associated
with a rapidly progressive increase in the extent of CAC,
whereas the use of sevelamer is associated with modest, if any,
increase in CAC score.1–3 The current analysis extends those
findings and shows that the use of sevelamer confers a
significant survival benefit as compared to the use of calcium-
containing phosphate binders. After adjustment for age, race,
gender, diabetes, and baseline CAC score, the use of calcium-
containing phosphate binders was associated with a doubling
of mortality. These results provide compelling evidence that
phosphate binder selection and mineral metabolism are linked
with mortality in subjects new to hemodialysis.
Of note, these data also demonstrate improved survival in
subjects with no CAC at the time of hemodialysis initiation.
As shown in the parent study,2 these subjects did not accrue
substantial calcification during the first 18 months of dialysis,
independent of phosphate binder treatment, and this appears
to have translated into a long-term survival benefit. This
observation suggests that a proportion of hemodialysis
subjects may be initially protected from progressive arterial
calcification via mechanisms which remain unclear but which
are associated with a favorable prognosis. It remains to be
elucidated whether active intervention to prevent or
attenuate vascular calcification in patients with earlier stages
of chronic kidney disease would ultimately impact long-term
outcomes once renal replacement therapy is initiated.
There are a few limitations to our analysis. This incident
population was modestly distinct from the generalized incident
population with respect to younger age and a higher prevalence
of diabetes. This analysis was carried out on an intent-to-treat
basis using the randomized binder as the treatment assignment
group. Patients were randomized to phosphate binder therapy
and followed for 18 months on the prescribed binder, but after
that time physicians were free to change phosphate binder
therapy at their discretion. Misclassification bias, however,
would reduce, rather than enhance, the likelihood of finding a
significant difference between randomized treatment groups.
The tendency to minimize any difference in outcome would be
true whether patients switched from sevelamer to calcium or
from calcium to sevelamer. Subjects treated with sevelamer
consistently experience a reduction in total and low-density
lipoprotein cholesterol.13 Although there has been recent
evidence that low-density lipoprotein reduction with statin
therapy does not have a demonstrable effect on survival in
diabetic patients undergoing dialysis,14 it remains possible that
the lipid lowering effects of sevelamer may have an affect on
all-cause mortality.
Lastly, it is worth noting that our results are not, on the
surface, consistent with the recent report (available in
abstract form only) from a large randomized trial comparing
all-cause mortality in dialysis subjects given either sevelamer
or calcium-containing phosphate binders (dialysis clinical
outcomes revisited). We believe this is likely attributable to
significant differences in study design. This prospective
randomized trial was conducted in patients new to
hemodialysis and followed for survival status over a median
follow-up of 44 months, whereas the dialysis clinical
outcomes revisited trial enrolled only subjects prevalent on
long-term dialysis (average 38 months) who had Medicare as
a primary payer and who were followed for a mean follow-up
of 20 months from randomization. It is noteworthy that in
the dialysis clinical outcomes revisited trial, those subjects
who were followed for at least 2 years did demonstrate a
survival benefit when treated with sevelamer, particularly in
the elderly subgroup (those who are likely to be the most
heavily calcified). Thus, the different population character-
istics, the shorter duration of follow-up and the inability to
discriminate those subjects who were more calcified from
those who were not calcified are likely to explain the
differences in results from our own report.
In summary, we have shown that the presence and severity
of CAC is a predictor of all-cause mortality in incident
hemodialysis patients and that the use of sevelamer as a
phosphate binder is associated with decreased mortality.
These data lend support to the Kidney Disease Outcomes
Quality Initiative guidelines regarding the preferential use of
sevelamer in the presence of cardiovascular calcification.15
These results further question the advisability of using
calcium-based phosphate binders as first line therapy.
MATERIALS AND METHODS
Between September 2000 and December 2002, 129 adult subjects
new to hemodialysis were randomized in blocks of 10 and stratified
by diabetic status to receive either calcium-containing phosphate
binders or sevelamer hydrochloride. The parent study was an 18-
month randomized, open-label clinical trial assessing the effect of
phosphate binders on progression of CAC detected by EBCT.2
During the study period, subjects remained on their assigned
phosphate binder. After the final scan, subjects were given phosphate
binders at the discretion of their primary nephrologist. Of the 129
subjects, two subjects from the parent study were subsequently
determined to have non-qualifying baseline EBCTs and were
excluded from this analysis. The remaining 127 patients comprised
the final study population. For all subjects, verification of vital status
was conducted through 31 December 2005 and assessed by chart
analysis and physician verification (GB, DS, PR) as well as
confirmation with the Social Security Death Index (http://ssdi.
rootsweb.com). The median follow-up time was 44 months.
LABORATORY AND IMAGING PROCEDURES
Routine biochemical measurements were obtained at baseline
and performed by the facilities usual laboratory (DaVita
Laboratories, Gambro Laboratories). EBCT imaging was
performed using a C-150 scanner (GE-Imatron, San
Francisco, CA, USA) according to a standard protocol as
described previously.3 CAC score quantification was per-
formed with the Agatston method.16
STATISTICAL ANALYSIS
One hundred and twenty-seven subjects who underwent a
baseline EBCT scan were included in the follow-up analysis
for occurrence of all-cause mortality. Comparison of baseline
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characteristics was done using the Fischer exact test for
categorical variables and the t-test for continuous variables.
Kaplan–Meier survival curves were generated and a log-rank
test was used to compare treatment group differences in time
to death. All outcomes other than death, including subjects lost
to follow up, subjects who underwent kidney transplant, and
subjects still alive at the end of the study period (31 December
2005), were censored. Mortality incidence rates (number of
deaths divided by patient-years of follow-up) and their 95%
CIs were calculated for each treatment group. Each of the
above analyses were performed separately for the entire
population as well as for subgroups based on baseline CAC
score. After verifying that the proportionality assumption of
the Cox proportional hazards regression model was valid,
mortality risk was assessed including baseline covariates known
to be predictive of mortality (age, race, gender, diabetes,
albumin, and Kt/V) and those variables found on univariate
analysis to have a Po0.10 (phosphate binder assignment,
baseline CAC score, history of atherosclerotic cardiovascular
disease and C-reactive protein). All P-values are two tailed.
Pp0.05 were considered statistically significant. Analyses were
conducted using SAS (version 8.2; Cary, NC, USA) and
GraphPad Prism software (version 4.0; San Diego, CA, USA).
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